

20th February, 2009

Press Release

The Genetics Company Inc. enters distributorship agreement with Stratech Scientific Ltd.

The Genetics Company Inc., a privately held Swiss company focusing on the development and commercialization of products for the research and diagnosis of Alzheimer's disease, is pleased to announce the closing of a distributorship agreement with Stratech Scientific Ltd. a leading distributor of life science research tools. Within the scope of this agreement, The Genetics Company will supply Stratech with its innovative beta-Amyloid (A β) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in the UK and Ireland.

Please find enclosed our press release. Thank you for your consideration and kind regards,



Dr. Matyas Vegh, CEO
vegh@the-genetics.com

www.the-genetics.com

PRESS RELEASE

Schlieren, Switzerland – 20th February, 2009

The Genetics Company Inc. enters distributorship agreement with Stratech Scientific Ltd.

The Genetics Company Inc., a privately held Swiss company focusing on the development and commercialization of products for the research, diagnosis and monitoring of Alzheimer's disease, is pleased to announce the closing of a distributorship agreement with Stratech Scientific Ltd., a leading distributor of life science research tools. Within the scope of this agreement, The Genetics Company will supply Stratech with its innovative beta-Amyloid (A β) detection tools for the diagnosis and research of neurodegenerative diseases, such as Alzheimer's disease and stroke, for distribution in the UK and Ireland

The Genetics Company's diagnostic and research tools enable the specific and selective detection of variants of human beta-Amyloid (A β), a key protein involved in the pathogenesis of several neurodegenerative diseases. The Company's products include very sensitive and reliable enzyme-linked immunosorbent assay (ELISA)-based test kits for the quantification of A β 40 and A β 42 in cerebrospinal fluid (CSF), plasma, cell lysate or tissue samples. While the corresponding A β 42/40 ratio has been validated by several studies as a superior biomarker for the diagnosis of incipient AD, the Company's test kits are also successfully used in clinical trials as drug monitoring tools or for pre-clinical research and development of A β lowering drugs. In addition, The Genetics Company's portfolio of A β -quantifying tools is complemented by highly selective monoclonal antibodies for the detection of A β , in particular A β 40 and A β 42.

Sharon Young, Director at Stratech Scientific Ltd. commented: "The Genetics Company's high quality research and diagnosis products will enable us to participate in and further develop the emerging field of neurodegenerative diseases in the UK and Ireland, especially in the areas of academic and industrial research as well as for *in vitro* diagnosis". Dr. Matyas Vegh, CEO at The Genetics Company added: "With Stratech we are pleased to have found the ideal partner to make our products available to customers in the UK and Ireland. This cooperation enables us to cover a highly attractive research and health care market in Europe".

About Stratech Scientific Ltd.

Stratech Scientific has been established since 1983 as a distributor of high quality, competitively priced, reliable products for research laboratories throughout the UK and Europe.

Currently Stratech Scientific supplies over 100,000 life science research tools from manufacturers around the world, providing a comprehensive range of antibodies, reagents and cells in areas such as immunology, cell biology and specialist fields like neuroscience.

About The Genetics Company, Inc.

The Genetics Company, Inc. is a dedicated team of entrepreneurs and scientists focusing on the development and commercialization of innovative products for the research, diagnosis and therapy monitoring of neurodegenerative diseases. Headquartered in Zurich-Schlieren, Switzerland, the Company currently employs a staff of 8.

For additional information about Stratech Scientific Ltd. please contact:

*Dr. Luke Scicluna
Stratech Scientific Ltd
Unit7, Acorn Business Centre
Oaks Drive, Newmarket
Suffolk, CB8 7SY
United Kingdom
Tel: +44-(0)-1638782600
Fax: +44-(0)-1638782606
E-mail: luke@stratech.co.uk
Web: www.stratech.co.uk*

For corporate information about The Genetics Company please contact:

*Dr. Matyas Vegh
The Genetics Company
Wagistrasse 23
CH-8952 Schlieren/Zürich
Switzerland
Tel: +41-44-2002230
Fax: +41-44-2002211
E-mail: vegh@the-genetics.com
Web: www.the-genetics.com*

For further information about The Genetics Company's products please contact:

*Dr. Antje Caelers
The Genetics Company
Tel: +41-44-2002266
Fax: +41-44-2002211
E-mail: caelers@the-genetics.com*